Ricardo Teixo

Mr. Ricardo Teixo


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2022 in Applied Sciences
Verified
Journal Article
Open access
PDF file
TGTarcísio Guerra Guimarães
Tarcísio Guerra Guimarães
KCKarla Menezes Cardoso
Karla Menezes Cardoso
CMCarlos Miguel Marto
Carlos Miguel Marto
RTRicardo Teixo
Ricardo Teixo
BSBeatriz Serambeque
Beatriz Serambeque
Mafalda LaranjoMafalda Laranjo
Mafalda Laranjo
Photodynamic therapy (PDT) in small animals’ oncology has been under research focus, pointing to new treatment possibilities. Moreover, several animal studies constitute experimental human disease models due to the similarity of tumor biology between animals and man. PDT uses photosensitizing compounds without toxicity per se. When subjected to a specific wavelength, the photosensitizers are activated, triggering the production of reactive oxygen species (ROS) that lead to cell death. Additionally, antiangiogenic effects and immune stimulation may also be elicited. PDT is minimally invasive, non-toxic, and does not induce carcinogenic or mutagenic side effects. Thus, it is safe for non-neoplastic tissues compared with other neoplasms treatment modalities. This review describes the applications of PDT in the cancer treatment of small animals, particularly dogs and cats, focusing on the respective photosensitizers and treatment protocols used in trials in this therapeutic modality.

Verified
Journal Article
Open access
PDF file
RTRicardo Teixo
Ricardo Teixo
Ana Salomé PiresAna Salomé Pires
Ana Salomé Pires
Eurico PereiraEurico Pereira
Eurico Pereira
BSBeatriz Serambeque
Beatriz Serambeque
Inês Alexandra MarquesInês Alexandra Marques
Inês Alexandra Marques
Maria Filomena BotelhoMaria Filomena Botelho
Maria Filomena Botelho
The increasing cancer incidence has certified oncological management as one of the most critical challenges for the coming decades. New anticancer strategies are still needed, despite the significant advances brought to the forefront in the last decades. The most recent, promising therapeutic approaches have benefitted from the application of human perinatal derivatives (PnD), biological mediators with proven benefits in several fields beyond oncology. To elucidate preclinical results and clinic outcomes achieved in the oncological field, we present a narrative review of the studies resorting to animal models to assess specific outcomes of PnD products. Recent preclinical evidence points to promising anticancer effects offered by PnD mediators isolated from the placenta, amniotic membrane, amniotic fluid, and umbilical cord. Described effects include tumorigenesis prevention, uncontrolled growth or regrowth inhibition, tumor homing ability, and adequate cell-based delivery capacity. Furthermore, PnD treatments have been described as supportive of chemotherapy and radiological therapies, particularly when resistance has been reported. However, opposite effects of PnD products have also been observed, offering support and trophic effect to malignant cells. Such paradoxical and dichotomous roles need to be intensively investigated. Current hypotheses identify as explanatory some critical factors, such as the type of the PnD biological products used or the manufacturing procedure to prepare the tissue/cellular treatment, the experimental design (including human-relevant animal models), and intrinsic pathophysiological characteristics. The effective and safe translation of PnD treatments to clinical practice relies on the collaborative efforts of all researchers working with human-relevant oncological preclinical models. However, it requires proper guidelines and consensus compiled by experts and health workers who accurately describe the methodology of tissue collection, PnD isolation, manufacturing, preservation, and delivery to the final user.

13 August 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SPSiri Paulo
Siri Paulo
Mafalda LaranjoMafalda Laranjo
Mafalda Laranjo
Ana Margarida AbrantesAna Margarida Abrantes
Ana Margarida Abrantes
RTRicardo Teixo
Ricardo Teixo
DFDiogo Fonseca
Diogo Fonseca
ASArmenio Serra
Armenio Serra
Background/Objectives: Osteonecrosis of the jaw, a non-healing wound, is a side effect in patients treated with nitrogen-containing bisphosphonates (e.g., zoledronate) after some oral procedures. Considering zoledronate toxicity in surgical wounds and the capacity of calcium phosphate synthetic compounds to adsorb it, the aim of this work was to demonstrate and elucidate the mechanism underlying this adsorption. Methods: Four different calcium phosphate synthetic bone substitutes were used in this study: AdBone® BCP (0.5–1 mm), Guidor® easy-graft (0.5–1 mm), Maxresorb® (0.5–1 mm) and Maxresorb® (0.8–1.5 mm). The materials were incubated in aqueous zoledronate solutions. Samples of the solutions obtained after 1, 2, 3, 6, 24, 48, 72 and 120 h of conditioning were then analyzed by spectrophotometry to measure their absorbance and subsequently characterized by micro-elemental analysis. Results: All four materials demonstrated time-dependent zoledronate adsorption. AdBone® BCP achieved the most rapid and sustained sequestration, reaching 80% reduction at 24 h and stabilizing at 85% from 72 h onwards without re-release. Maxresorb® formulations showed comparable kinetics through 72 h (70–75%) but exhibited partial re-release at 120 h. Guidor® easy-graft showed negligible adsorption through the first 24 h, consistent with the physical barrier effect of its PLGA coating. Spectrophotometric findings were independently confirmed by elemental analysis. Conclusions: This work confirms zoledronate adsorption by calcium phosphate synthetic biomaterials. Among the tested materials, AdBone® BCP demonstrated the most favorable adsorption profile, with kinetics well matched to the critical window of alveolar wound healing. These findings support the use of biphasic calcium phosphate bone substitutes as a local strategy to reduce free zoledronate bioavailability at the surgical site, potentially lowering the risk of MRONJ in patients undergoing dentoalveolar procedures under bisphosphonate therapy.

5 February 2026 in Dentistry Journal
Verified
Journal Article
Open access
PDF file
SPSiri Paulo
Siri Paulo
PZPedro Zagalo
Pedro Zagalo
BLBeatriz Louro
Beatriz Louro
RTRicardo Teixo
Ricardo Teixo
JMJose Martinho
Jose Martinho
MFManuel Marques Ferreira
Manuel Marques Ferreira
Background/Objectives: Root canal instrumentation has a crucial role in the success of endodontic treatment. However, management of curved root canals remains a challenge. This study aimed to compare the performance of four rotatory file systems, ProTaper Next, TruNatomy, ProTaper Ultimate and Race Evo, in terms of wear, transportation and centering capacity, in curved root canals. Methods: A total of 150 human tooth roots were selected, divided based on the degree of curvature, and then distributed into four experimental groups according to the rotary system used. Cone beam computed tomography images were obtained before and after instrumentation, and values were measured with ImageJ software. Results: Regarding root canal wear, the TruNatomy system displayed the lowest wear values, and the Race Evo system showed a tendency for greater wear. For transportation, TruNatomy and Race Evo had the lowest transportation, indicating a higher respect for the root canal’s original anatomy. For centering ability, Race Evo and ProTaper Ultimate displayed values closer to perfect centering compared to other systems. Conclusions: Overall, TruNatomy was confirmed as a more conservative system, Race Evo with a tendency for greater wear even though with a higher respect for root canal original anatomy. Race Evo and ProTaper Ultimate showed better centering ability.